
Volunteers who took part in a trial of a microbicide listened to results in Vulindlela, Kwazulu-Natal Province, South Africa. Joao Silva for The New York Times
From Celia W. Dugger in the New York Times:
JOHANNESBURG — When scientists celebrated the announcement in July that a vaginal microbicide had finally been found that significantly reduced H.I.V. infections in women, there was still a prosaic — though essential — piece of the puzzle missing: money.
Donors have not committed enough money for even one of the two studies needed to confirm a promising South African trial of the microbicide and get it into women’s hands. Only about $58 million of the $100 million needed for follow-up research has been pledged, according to Unaids, the United Nations AIDS agency. Experts say shifting global health priorities and tight finances in the West are making it hard to raise the rest.
Advocates say any delay could be deadly. Most of the 22 million people infected with H.I.V. in sub-Saharan Africa are women, and about a million women on the continent are infected each year. If subsequent studies find the gel effective, women could use it to protect themselves even when men refuse to use condoms.
“We have to keep our eye on the prize,” said Dr. Catherine Hankins, chief scientific adviser to Unaids. “It’s in reach. We have to close the funding gap and get the gel to women.”
![[rss]](http://science-society.com/wp-content/themes/k2_1.0.3/images/feed.png)

From Steven Shapin in the London Review of Books:
From Eric Benson and Justin Nobel in
John Markoff reviews W. Brian Arthur’s The Nature of Technology in the New York Times,
